Roche (RHHBY) announced the European Commission has approved Xofluza in children aged one year and above for the treatment of uncomplicated influenza and for post-exposure prophylaxis of influenza. The approval is based on the results of the phase III miniSTONE-2 and BLOCKSTONE studies.
Xofluza was first approved for use in Europe in 2021 for the treatment of uncomplicated influenza and for post-exposure prophylaxis of influenza in adults and adolescents aged 12 years and above. The company is continuing to investigate Xofluza in phase III trials in children under the age of one.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News